Completed PHASE2 INTERVENTIONAL 1-arm NCT01016015

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Osteosarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Osteosarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma

Interventions Cixutumumab Laboratory Biomarker Analysis Temsirolimus

Updated 7 times since 2017 Last updated: Jul 2, 2015 Started: Nov 30, 2009 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01016015, this PHASE2 trial focuses on Metastatic Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Charleston, United States , Charlotte, United States , Chicago, United States , Decatur, United States , Edmonton, Canada , Evanston, United States , Houston, United States , Jacksonville, United States and 11 more locations